Validation of ZIP4 as a tumour-associated antigen for nanotargeting

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Xu, Ruixue
• dc.contributor.author Martínez Bosch, Neus
• dc.contributor.author Rivera Hueto, Francisco
• dc.contributor.author Mulens-Arias, Vladimir
• dc.contributor.author Rubio Moscardó, Fanny
• dc.contributor.author Conesa, José Javier
• dc.contributor.author Navarro, Pilar
• dc.contributor.author Vicente García, Rubén, 1978-
• dc.contributor.author Rivera Gil, Pilar, 1976-
• dc.date.accessioned 2024-11-15T07:14:59Z
• dc.date.available 2024-11-15T07:14:59Z
• dc.date.issued 2024
• dc.description Data de publicació electrònica: 01-10-2024
• dc.description.abstract Pancreatic ductal adenocarcinoma remains a highly aggressive and untreatable cancer. There is a need to develop a new PDAC-associated antigen-targeting drug delivery system to tackle this disease. We validated choosing ZIP4 as a putative target in PDAC theranostics. We developed a nanosystem composed of a fluorescent polystyrene core coated with gold nanoparticles onto which a ZIP4-specific polyclonal antibody is attached. The polystyrene core's fluorescence properties allow the nanosystem tracking by intravital imaging. We also developed two ZIP4-expressing cell lines by stably transfecting HEK293 and RWP1 cells with a ZIP4-coding plasmid that simultaneously provides cells with puromycin resistance. We studied the cell internalisation of the as-synthesised nanoparticles and demonstrated that ZIP4-expressing HEK293 and ZIP4-expressing RWP1 cells tended to take up more ZIP4-targeting nanoparticles. Moreover, we observed that ZIP4-targeting nanoparticles accumulated more in ZIP4-expressing HEK293 and RWP1 tumours when injected intravenously in a subcutaneous xenograft and an orthotopic in vivo model, respectively. Furthermore, the administration of these nanoparticles did not induce any significant systemic toxicity as determined by histological analysis of all organs. Altogether, these results provide the first evidence of the feasibility of using a ZIP4-targeting nanosystem further to design efficient therapeutic and diagnostic tools for PDAC.
• dc.description.sponsorship Pilar Rivera Gil (PRG) acknowledges the Ministry of Science, Innovation and Universities (MICINN-AEI): CNS2023 - 143700 - MICIU/AEI/10.13039/501100011033/Unión Europea NextGenerationEU/PRTR and PID2022-140423NB-I00 for financial support. Rubén Vicente acknowledges the MICINN-AEI (PID2022-136511OB-I00). PRG acknowledges the AGAUR (Agència de Gestió d’Ajuts Universitaris i de Recerca) (2021 SGR 00175 and 2021 PROD 00041) for financial support. This work was also supported by grants from the Spanish Ministry of Science and Innovation (MICINN)/Instituto de Salud Carlos III (ISCIII)-European Regional Development Fund (ERDF) (PI20/00625 and PI23/00591) to Pilar Navarro.
• dc.format.mimetype application/pdf
• dc.identifier.citation Xu R, Martinez-Bosch N, Rivera-Hueto F, Mulens-Arias V, Rubio-Moscardo F, Conesa JJ, et al. Validation of ZIP4 as a tumour-associated antigen for nanotargeting. J Drug Target. 2024 Oct 1:1-13. DOI: 10.1080/1061186X.2024.2405711
• dc.identifier.doi http://dx.doi.org/10.1080/1061186X.2024.2405711
• dc.identifier.issn 1061-186X
• dc.identifier.uri http://hdl.handle.net/10230/68699
• dc.language.iso eng
• dc.publisher Taylor & Francis
• dc.relation.ispartof J Drug Target. 2024 Oct 1:1-13
• dc.relation.projectID info:eu-repo/grantAgreement/ES/3PE/PID2022-140423NB-I00
• dc.relation.projectID info:eu-repo/grantAgreement/ES/3PE/PID2022-136511OB-I00
• dc.rights © 2024 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
• dc.subject.keyword Molecular targeting
• dc.subject.keyword ZIP4
• dc.subject.keyword Biodistribution
• dc.subject.keyword Drug delivery nanosystems
• dc.subject.keyword Histopathological analysis
• dc.subject.keyword Pancreatic ductal adenocarcinoma (PDAC)
• dc.title Validation of ZIP4 as a tumour-associated antigen for nanotargeting
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion